Aktienanalyse zu Icecure Medical Ltd (ICCM)ICCMIcecure Medical Ltd

Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized. It operates in the Healthcare sector.

Icecure Medical Ltd is not a good buy right now due to its current price of $0.68, which is significantly below its 52-week high of $22.50, indicating a dramatic decline of 96.40% year-to-date. Additionally, the RSI is extremely low at 10.421, suggesting the stock is oversold, but this could also indicate a lack of buying interest. The company has reported a widening net loss of $4.5 million in Q2 2026, and its gross margin has decreased to 27.89%. The main risk is the upcoming earnings report on November 18, 2026, where the EPS estimate is -0.83, which could further impact the stock negatively if results do not meet expectations.